FDA Panel Votes in Favor of Effectiveness of Forest Labs’ Daxas – Dow Jones reports that US FDA Panel has voted 9-6 in favor of Forest Labs (FRX), Nycomed drug Daxas which has shown effectiveness for COPD maintenance.